Pure Global

IGF Level in Breast Cancer Patients Treated With Metformin - Trial NCT05840068

Access comprehensive clinical trial information for NCT05840068 through Pure Global AI's free database. This Phase 4 trial is sponsored by Beni-Suef University and is currently Completed. The study focuses on Breast Cancer Female. Target enrollment is 107 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05840068
Phase 4
Completed
drug
Trial Details
ClinicalTrials.gov โ€ข NCT05840068
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
IGF Level in Breast Cancer Patients Treated With Metformin
Metformin Effect as a Chemotherapeutic Adjuvant on Level of IGF in Non-diabetic Breast Cancer Patients

Study Focus

Breast Cancer Female

MetFORMIN 500 Mg Oral Tablet

Interventional

drug

Sponsor & Location

Beni-Suef University

Banฤซ Suwayf, Egypt

Timeline & Enrollment

Phase 4

Jun 01, 2020

Jul 31, 2021

107 participants

Primary Outcome

IGF-1 levels

Summary

The purpose of this study is to examine the impact of metformin as an adjuvant to
 chemotherapy on IGF levels in both progressing and non progressing cases of metastatic breast
 cancer in female patients.

ICD-10 Classifications

Malignant neoplasm: Breast, unspecified
Malignant neoplasm of breast
Malignant neoplasm of breast
Carcinoma in situ of breast, unspecified
Personal history of malignant neoplasm of breast

Data Source

ClinicalTrials.gov

NCT05840068

Non-Device Trial